Nateglinide - Revision history

Prab: CSV import

2025-02-20T01:45:34Z

CSV import

← Older revision		Revision as of 01:45, 20 February 2025
Line 42:		Line 42:
	[[Category:Antidiabetic drugs]]		[[Category:Antidiabetic drugs]]
	[[Category:Meglitinides]]		[[Category:Meglitinides]]
			<gallery>
			File:Nateglinide.svg\|Nateglinide
			</gallery>

Prab: CSV import

2025-02-13T03:45:06Z

CSV import

← Older revision		Revision as of 03:45, 13 February 2025
Line 1:		Line 1:
	{{~~intro~~}}		{{Short description\|An oral antidiabetic medication}}
	Nateglinide ~~is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]]~~.		{{Drugbox
			\| verifiedfields = changed
			\| verifiedrevid = 477002123
			\| image = Nateglinide.svg
			\| image2 = <!-- Another image if available -->
			}}

	~~{{livtox}}~~		'''Nateglinide''' is an oral [[antidiabetic drug]] used in the management of [[type 2 diabetes mellitus]]. It belongs to the class of medications known as [[meglitinides]], which stimulate the [[pancreas]] to release [[insulin]].
	Nateglinide ~~has been linked~~ to ~~rare instances~~ of ~~clinically apparent acute liver injury~~.

	~~{{moa}}~~		==Mechanism of Action==
	Nateglinide ~~(na teg' li nide) is an insulin secretagogue that is similar in action but different in structure from~~ the ~~sulfonylureas. It is a derivative of phenylalanine and stimulates insulin secretion by blocking~~ ATP sensitive potassium ~~channels~~ in ~~pancreatic~~ beta-cells, ~~causing cell membrane depolarization which results~~ in calcium ~~influx~~ and insulin ~~secretion~~. ~~Nateglinide has been shown to reduce the postprandial increase in glucose~~ in ~~patients with~~ [[~~type 2 diabetes~~]] ~~and improve glycemic control~~. ~~Nateglinide~~		Nateglinide works by closing the [[ATP-sensitive potassium channel]]s in the [[beta cells]] of the [[pancreas]]. This action leads to the opening of [[calcium channels]], resulting in an influx of [[calcium ions]] and subsequent release of insulin. The drug is particularly effective in controlling [[postprandial blood glucose]] levels.

	~~{{fda}}~~		==Pharmacokinetics==
	~~{{PAGENAME}} was approved for use~~ in the ~~United States in 2000~~.		Nateglinide is rapidly absorbed from the [[gastrointestinal tract]] and has a quick onset of action. It is metabolized primarily in the [[liver]] by the [[cytochrome P450]] enzyme system, particularly [[CYP2C9]] and [[CYP3A4]]. The drug has a short half-life, which minimizes the risk of [[hypoglycemia]].

	~~{{use}}~~		==Clinical Use==
	~~The current indications are~~ for ~~management~~ of [[type 2 diabetes]] ~~used~~ in ~~combination~~ with [[diet]] and [[exercise]], with or ~~without other oral~~ [[~~hypoglycemic agents~~]]~~. Nateglinide is available generically and under the brand name Starlix in tablets of 60 and 120 mg~~.		Nateglinide is indicated for the treatment of [[type 2 diabetes mellitus]] in conjunction with [[diet]] and [[exercise]]. It is often used in combination with other antidiabetic agents such as [[metformin]] or [[thiazolidinediones]].

	~~{{dose}}~~		==Side Effects==
	~~The typical initial dose in adults is 120 mg three times daily before meals.~~		Common side effects of nateglinide include:
			* [[Hypoglycemia]]
			* [[Upper respiratory tract infection]]
			* [[Dizziness]]
			* [[Joint pain]]

	~~{{se}}~~		==Contraindications==
	~~Side effects of nateglinide include~~ [[~~diarrhea~~]], [[~~nausea~~]]~~, gastrointestinal upset, [[hypoglycemia]], [[dizziness]] and [[rash]].~~		Nateglinide is contraindicated in patients with:
			* [[Type 1 diabetes mellitus]]
			* [[Diabetic ketoacidosis]]
			* Known hypersensitivity to the drug

	~~{{antidiabetic~~ drugs}}		==Administration==
	~~{{coststubd}}~~		Nateglinide is administered orally, typically taken before meals to optimize its effect on postprandial glucose levels.

			==Related pages==
			* [[Type 2 diabetes mellitus]]
			* [[Insulin]]
			* [[Meglitinides]]
			* [[Hypoglycemia]]

			[[Category:Antidiabetic drugs]]
			[[Category:Meglitinides]]

Prab: Created page with "{{intro}} Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabet..."

2019-04-26T15:05:51Z

Created page with "{{intro}} Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of type 2 diabet..."

New page

{{intro}}
Nateglinide is an oral hypoglycemic agent and amino acid derivative that stimulates insulin secretion from the pancreas and is used in the therapy of [[type 2 diabetes]].

{{livtox}}
Nateglinide has been linked to rare instances of clinically apparent acute liver injury.

{{moa}}
Nateglinide (na teg' li nide) is an insulin secretagogue that is similar in action but different in structure from the sulfonylureas. It is a derivative of phenylalanine and stimulates insulin secretion by blocking ATP sensitive potassium channels in pancreatic beta-cells, causing cell membrane depolarization which results in calcium influx and insulin secretion. Nateglinide has been shown to reduce the postprandial increase in glucose in patients with [[type 2 diabetes]] and improve glycemic control. Nateglinide

{{fda}}
{{PAGENAME}} was approved for use in the United States in 2000.

{{use}}
The current indications are for management of [[type 2 diabetes]] used in combination with [[diet]] and [[exercise]], with or without other oral [[hypoglycemic agents]]. Nateglinide is available generically and under the brand name Starlix in tablets of 60 and 120 mg.

{{dose}}
The typical initial dose in adults is 120 mg three times daily before meals.

{{se}}
Side effects of nateglinide include [[diarrhea]], [[nausea]], gastrointestinal upset, [[hypoglycemia]], [[dizziness]] and [[rash]].

{{antidiabetic drugs}}
{{coststubd}}